Literature DB >> 24104543

T-lymphocytes are directly involved in the clinical expression of migratory circinate erythema in epidermolysis bullosa simplex patients.

Daniele Castiglia1, May El Hachem, Andrea Diociaiuti, Teresa Carbone, Naomi De Luca, Monica Pascucci, Giovanna Zambruno, Andrea Cavani.   

Abstract

Epidermolysis bullosa simplex with migratory circinate erythema (EBS-MCE) is a rare EBS subtype characterised by migratory blistering lesions that resolve with brownish pigmentation. It is caused by a recurrent readthrough mutation, c.1649delG, in the tail of keratin 5. Here, we report a child with EBS-MCE and investigated the immunologic mechanisms underlying the migratory lesions in this patient. A skin biopsy from the patient from an active border of an erythematous lesion was used for the immunohistochemical characterisation of the inflammatory infiltrate and for TUNEL assay to detect apoptotic cells. We found abundant CD4+ and CD8+ T lymphocytes infiltrating the papillary dermis and lining the dermal-epidermal junction. A number of these cells expressed the activation marker CD69. CD83+ dendritic cells were present both in the epidermis and papillary dermis. Finally, TUNEL staining showed apoptosis of basal and suprabasal keratinocytes. These findings suggest a critical role of the cellular immunity in determining the EBS-MCE phenotype.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24104543     DOI: 10.2340/00015555-1691

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

Review 1.  Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex.

Authors:  Nadezhda A Evtushenko; Arkadii K Beilin; Anastasiya V Kosykh; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

2.  Severe hyponatremia in an infant with epidermolysis bullosa: a case report.

Authors:  Soheil Dehghani; Boshra Akbarzadeh Pasha; Amirali Karimi; Azadeh Afshin
Journal:  J Med Case Rep       Date:  2022-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.